Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
-
+
EP05.01-011 - Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience.
Presenter: Joel Rivera Concepcion- Abstract
Loading...
-
+
EP14.05 - Small Cell Lung Cancer and Neuro-endocrine Tumors - RW/SOC
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Small Cell Lung Cancer and Neuro-endocrine Tumors - RW/SOC
-
+
EP14.05-001 - Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3
Presenter: Muskan Agarwal- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
MA13.07 - TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
12:27 - 12:32 | Presenter: Benjamin Levy
- Abstract
Loading... -
+
MA13.09 - Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer
12:37 - 12:42 | Presenter: Sagar Rakshit
- Abstract
Loading...
